drugset
drugset / Trial / NCT00017680

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

NCT00017680 ↗

Phase 2 Completed 25 enrolled Herbert Irving Comprehensive Cancer Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

OBJECTIVES: I. Determine the response, disease-free survival, and overall survival of patients with primary light chain amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. II. Determine the toxicity of this regimen in these patients.

Timeline

Start
1999-07
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule 100 mg/m2 Intravenous

Indications

amyloidosis